Who We Are

Dr. Ballal has more than 15 years of life sciences experience in business development, strategic partnerships, venture capital, and company financing. He joined Imara from Northern Biologics and Versant Ventures where he served as Chief Business Officer and an Entrepreneur-in-Residence, respectively. At Northern, he built a first-in-class immuno-oncology portfolio, led a broad strategic partnership with Celgene, and managed several key functional roles at the executive level. At Versant, he negotiated foundational assets for existing portfolio and new companies, sourced several new deals, and participated in investment team activities.

Previously, Dr. Ballal was Vice President, Business Development at Flexion Therapeutics, where he led several business development transactions, supported multiple functions during the initial public offering, and completed a key $175MM strategic partnership with Patheon UK, for dedicated commercial manufacturing. Prior to Flexion, he held business development and leadership positions at Novartis Venture Fund; Broad Institute of MIT and Harvard; and Redmind Inc. Dr. Ballal earned a B.S. in biology from Brown University, a M.S. in bioinformatics from Johns Hopkins University, and a Ph.D. in biochemistry from Georgetown University. He is also a Kauffman Fellow.

Mr. Gray brings nearly two decades of experience to Imara at both public and private biotechnology and large pharma companies, where he developed strong investment community relationships and an in-depth understanding of capital markets, with a background in business operations, strategic corporate finance, business development and investor relations. He most recently served as President, Chief Executive Officer and Chief Financial Officer at public, global biotechnology company, Arsanis, Inc., leading a strategic process that consummated with the closing in March 2019 of a merger between Arsanis and X4 Pharmaceuticals following a futility outcome of Arsanis’ lead clinical asset. Mr. Gray previously served as Arsanis’ Chief Operating and Chief Financial Officer from March 2016 until November 2018. In that capacity, he built the business and finance infrastructure of Arsanis’ U.S. global headquarters and successfully raised over $130 million, including completing two private financings and an initial public offering (IPO).

Prior to Arsanis, Mr. Gray spent over a decade at Curis, Inc., a publicly-traded oncology company, including 13 years as its Chief Financial Officer, while also holding dual roles as either Chief Operating Officer or Chief Business Officer during most of his tenure. At the company, he was responsible for financial strategy and business operations, business development, alliance management, corporate legal as well as all other administrative functions. Mr. Gray raised approximately $200 million in equity capital through a variety of transactions, including public offerings, at-the-market (ATM) offerings, registered direct offerings, PIPEs and other structures. He was the business development and finance lead for a potentially transformative collaboration agreement with Aurigene and led the 2012 in-licensing of a clinical-stage compound from Genentech and simultaneous $30 million structured debt transaction. Mr. Gray was also instrumental in Curis’ entry into and subsequent management of its collaboration with Genentech (Roche) that was focused on the Hedgehog signaling pathway, which resulted in a commercially approved drug for the treatment of advanced basal cell carcinoma. Previously, Mr. Gray was Controller and de Facto Chief Financial Officer at Reprogenesis, Inc., where he participated in various financings and managed all preclinical and clinical development financial activities. He began his career as an audit professional with Ernst & Young, LLP.

Mr. Gray earned his BS in business administration with an accounting concentration from Bryant College in Smithfield, Rhode Island, and his MBA, finance and entrepreneurial management concentration, from Babson College in Wellesley, Mass. He is a certified public accountant and a member of the American Institute of Certified Public Accountants (AICPA) and the Association of Biotech Financial Officers (ABFO).

Ms. Hopkinson has extensive experience leading global regulatory teams in strategy, labeling and advertising and promotion within the pharmaceutical and biotech industries. Prior to joining Imara, Ms. Hopkinson served as Vice President, Global Head of Cystic Fibrosis Regulatory Strategy and Commercial Regulatory Affairs at Vertex Pharmaceuticals where she oversaw  early and late-stage development programs, as well as line-extension programs for marketed products, and as Vice President, Head of North America Regulatory Strategy and Commercial Affairs, where she oversaw marketed products, the submission and approval of Trikafta^®, as well as clinical development candidates, including the CRISPR Cas-9 programs in sickle cell disease and beta thalassemia. Previously Ms. Hopkinson held Regulatory Affairs roles of increasing responsibility at Eisai, Inc. and Genentech, Inc., where she supported the approvals of multiple new drugs including Halaven^®, Fycompa^®, Belviq^® and Lucentis^®. Ms. Hopkinson earned her B. Pharm and Management Advancement certificate from the University of Witwatersrand in Johannesburg, South Africa.

Ms. Lufkin brings more than 20 years of global experience overseeing all phases of clinical trials and drug development across multiple therapeutic areas to Imara. She is an accomplished leader who has driven the advancement of programs from clinical proof of concept through regulatory approval.

Before joining Imara, Ms. Lufkin held multiple roles during more than seven years at Flexion Therapeutics, most recently as Vice President of Clinical Development overseeing clinical operations, data management, biostatistics and medical writing across the company’s pipeline programs. At Flexion, she led the clinical development program for Zilretta^® from the product’s investigational new drug (IND) application through approval by the U.S. Food and Drug Administration (FDA). Previously, she served in clinical operations and clinical trials management roles of increasing responsibility at Synta Pharmaceuticals and Cubist Pharmaceuticals.

Ms. Lufkin earned her B.S. in biology from the University of Massachusetts Amherst and her M.P.H. from Boston University School of Public Health.

Mr. Migausky has extensive experience leading corporate legal and governance teams. Prior to joining Imara, he served as General Counsel at ArQule, Inc., a publicly traded company, where he led the legal and compliance function over the past two years and served as a key advisor in the company’s acquisition by Merck  for $2.7 billion. Previously, he served in roles of increasing responsibility at Vertex Pharmaceuticals Inc. where he was responsible for SEC reporting and corporate law.  Mr. Migausky began his legal career as a corporate attorney at Wilmer Cutler Pickering Hale and Dorr.  Mr. Migausky earned a B.A. in economics and history from Colby College and his J.D. from the Georgetown University Law Center.

Ms. Rau is an accomplished quality executive with 20 years of leadership experience guiding drug development from early-stage R&D through commercialization. Previously serving as Vice President of Global Quality at Sucampo Pharmaceuticals, Inc., Ms. Rau led the quality management system across the company’s domestic and international sites to support product development activities and commercial products. Prior to that, she held roles of increasing responsibility at Prometheus Laboratories, Inc., before moving on to develop and lead the execution of quality strategy at Auspex Pharmaceuticals, Inc. as Vice President of Quality and Quality Assurance. Ms. Rau earned her B.A. in biology from the University of North Carolina, Chapel Hill and completed a regulatory affairs certification in medical devices and pharmaceuticals from the Regulatory Affairs Professional Society.

Mr. Waligora comes to Imara from Curis, Inc., where he served as Vice President of Chemistry, Manufacturing and Controls (CMC) since 2015. In this role he led the development, manufacturing and distribution of several small molecule oncology products for the company’s clinical trials. In previous roles, Mr. Waligora held positions of increasing responsibility for chemical development and production of drug substances and drug products. He earned his M.B.A. from Northeastern University and his B.S. in chemistry from Rochester Institute of Technology.

Mr. Mott is a private investor through Mott Family Capital.  From September 2008 to February 2020, Mr. Mott was general partner at New Enterprise Associates (“NEA”) and led the healthcare investing practice.  NEA is among the largest venture capital firms in the world and invests across all stages in healthcare and technology.  At NEA, Mr. Mott’s personal investing practice was primarily focused on biopharmaceuticals.

Prior to joining NEA, Mr. Mott was president and chief executive officer of biotechnology company MedImmune.  He joined MedImmune in 1992 and served in various roles, including president and chief executive officer from October 2000 through July 2008 and previously chief financial officer and president and chief operating officer.  Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion.  Earlier in his career, he was a vice president in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc.  Across his career, as chairman, chief executive officer, board member, general partner or operating executive, Mr. Mott has been involved in over $40 billion in corporate acquisitions, fundraising, partnerships and other capital formation.  He has been involved in more than 35 initial public offerings or corporate acquisitions, in bringing over a dozen new drugs through development to commercialization, and has served on 25 corporate boards.

Mr. Mott is currently Chairman of several public biotechnology companies: Adaptimmune (ADAP), Ardelyx (ARDX), Epizyme (EPZM), Imara (IMRX), and Mersana (MRSN).  Mr. Mott earned a B.A. from Dartmouth College.

Mette Kirstine was previously co-founder and CEO of 7TM Pharma A/S and has a broad international experience within biotech/life science covering business development and licensing, management and financing. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.

Mette is a board member of Cydan Development, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals, Veloxis and Vtesse.

Dr. Ballal is CEO of Imara and has more than 15 years of life sciences experience in business development, strategic partnerships, venture capital, and company financing. He joined from Northern Biologics and Versant Ventures where he was Chief Business Officer and an Entrepreneur-in-Residence, respectively. At Northern, he built a first-in-class immuno-oncology portfolio, led a broad strategic partnership with Celgene, and managed several key functional roles at the executive level. At Versant, he negotiated foundational assets for existing portfolio and new companies, sourced several new deals, and participated in investment team activities. Previously, Dr. Ballal was Vice President, Business Development at Flexion Therapeutics, where he led several business development transactions, supported multiple functions during the initial public offering, and completed a key $175MM strategic partnership with Patheon UK, for dedicated commercial manufacturing. Prior to Flexion, he held business development and leadership positions at Novartis Venture Fund; Broad Institute of MIT and Harvard; and Redmind Inc. Dr. Ballal earned a Bachelor’s degree in Biology from Brown University, a Master’s degree in Bioinformatics from Johns Hopkins University and a Ph.D. in Biochemistry from Georgetown University. He is also a Kauffman Fellow.

Dr. David Bonita has more than 15 years of investment and financial experience with private equity and investment banking companies. He is currently a private equity partner at OrbiMed. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his bachelor of arts degree magna cum laude in biological sciences from Harvard University and his joint medical doctorate/master of business administration from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.

Mark Chin currently sits on the board of Iterum Therapeutics, Harpoon Therapeutics and Imara. He was previously an Investment Director at Arix Bioscience and principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, Chin was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. Chin has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

Edward Conner currently serves as Senior Vice President and Chief Medical Officer at Audentes Therapeutics, An Astellas Company, where he is responsible for leading the global clinical development strategy and oversees clinical development, clinical operations, regulatory affairs, medical affairs and patient advocacy. Previously, he served as Senior Vice President and Chief Medical Officer at Sangamo Therapeutics, Inc., where he led the clinical development of the company’s pipeline of genomic therapies. Prior to Sangamo, he served in senior clinical and medical leadership positions at Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., and Genentech, Inc., where he oversaw the clinical development of multiple late-stage clinical programs in both rare and broader disease areas. Dr. Conner completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.

Barbara Dalton joined Pfizer in 2007 to manage the Pfizer Ventures Investments team within Worldwide Business Development. She is responsible for growing their corporate venture activities, managing the corporation's private equity portfolio, advising on structured equity transactions and driving novel transactions to achieve corporate objectives. Dr. Dalton has more than 20 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in indirect and direct health care investments in more than 40 funds and over 100 companies in the U.S. and Europe.  She has had direct investing responsibility for biotechnology therapeutic and platform companies, as well as some healthcare IT and service businesses.  She is currently on the board of Cydan, Vtesse, Ixchelsis, The Accelerator Crop, Petra and Lodo and supports several other PVI portfolio companies as a board observer.  Dr. Dalton began her pharmaceutical career as a research scientist in immunology at SmithKline and French Laboratories and joined their venture capital group, SR One, Limited in the early 1990's. She was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner.

Dr. Dalton has also been supportive of the many regional and national organizations encouraging innovative startups in health care. She chaired the Philadelphia regional venture investors association, (fka the MAC Alliance), and has been a member of the National Venture Capital Association Board. She also supported the venture philanthropy efforts of the Institute for the Study of Ageing as a Board member. Currently she is the chair of the advisory board for the health care sector of the New York City Investment Fund and an advisor to the Dean of the Eberly College of Science, at Penn State where she received her undergraduate degree.  She received a PhD in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).

Carl Goldfischer, MD, is a Managing Director of Bay City Capital, and has been with the firm since 2000.  He has invested across all subsectors within the life sciences industry and his expertise spans both private and public markets.  In addition, he brings deep operational experience in finance, clinical trial development, and clinical medicine.

During his career, Dr. Goldfischer has lead and served on the board of directors of innumerable public and private companies including: Epizyme, MAP Pharmaceuticals, Oculex, Cymabay, Cydan and Pharmakea. Most recently his was the founder and is Executive Chairman of Bridge Medicines, a novel partnership between Bay City Capital, Memorial Sloan Kettering, Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company. This novel partnership aims to take programs from the universities laboratories, seamlessly through human proof of concept.  

Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of publicly traded biotech company ImClone Systems where he oversaw financial operations and strategic planning.  Previously, he was a Health Care Research Analyst with the Reliance Insurance Company and was a Director of Research at D. Blech & Co.  He began his career as a radiation oncologist at Montefiore Hospital, part of the Albert Einstein College of Medicine.  Dr. Goldfischer received an MD with honors in Scientific Research from Albert Einstein College of Medicine and a BA from Sarah Lawrence College.

Sara joined NEA's healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana, Cydan, Vtesse and Therachon, and as a board observer for Loxo Oncology (LOXO), Ziarco, Clementia, Millendo, and NightstaRx. She previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, and Proteostasis.

Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.

Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.